Amgen BeOne — Total revenues remained flat by 0.0% to $66.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 2.7%, from $64.75M to $66.50M. Over 2 years (FY 2023 to FY 2025), BeOne — Total revenues shows an upward trend with a 45.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates successful market penetration, higher demand, or effective commercial execution for the products within this segment, while a decrease may signal competitive pressure, patent cliffs, or declining market interest.
This metric represents the total gross revenue generated from products or services associated with the specific strategi...
Comparable to revenue reporting for specific strategic alliances, joint ventures, or licensed product portfolios at other large-cap biotechnology or pharmaceutical companies.
amgn_segment_beone_total_revenues| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $125.00M | $259.00M | $266.00M |
| YoY Change | — | +107.2% | +2.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.